ESR1 and breast cancer: A limitation of this study is that while the summary statistics of GWAS used in our study were derived from the study participants from all breast cancer subtypes, TF ChIP-seq data were primarily from cell lines of ER+ breast cancer (e.g., MCF7) and ChIP-seq data from cell lines of ER− breast cancer were limited.